Eli Lilly Stock Split Speculation Mounts as Share Price Holds Above $1,000

Market analysts are increasingly discussing the possibility of Eli Lilly executing a stock split following its share price surpassing the $1,000 mark. The speculation is driven by the company’s 160% share price growth over the past three years, its dominant 60% share of US GLP-1 prescriptions, and the recent launch of the oral obesity drug Foundayo. While stock splits are often utilised to lower per-share prices to attract retail investors, Eli Lilly did not split when the price first exceeded $1,000 late last year. The company has executed four splits in its history, with the most recent occurring in the late 1990s.

The discussion centres on the psychological barrier that the $1,000 price point represents for some investors. Stock splits are typically employed to bring down the individual share price, thereby making the stock more accessible to retail investors who may not have access to fractional shares. This strategy is not unique to the pharmaceutical sector; market giants such as Nvidia and Walmart have executed similar operations in recent years after seeing their stock prices soar, signalling management optimism about future growth.

Eli Lilly’s market position has strengthened significantly, slipping ahead of rival Novo Nordisk to control approximately 60% of the GLP-1 drug market in the United States. This dominance has translated into blockbuster revenue, with shares advancing more than 160% over the past three years. Although the stock struggled in the first months of the current year, it has surged in the past month, reclaiming the $1,000 level after previously breaching it late last year without triggering a split.

A key factor in the current momentum is the recent launch of Foundayo, an oral obesity pill that may serve as a new growth driver alongside existing injectable blockbusters Mounjaro and Zepbound. Data cited by Fierce Pharma on May 22, referencing a Citi note, indicates that GLP-1 prescriptions increased by 3.6% over a recent four-week period, compared to a 1.8% increase a year earlier. This growth in prescriptions underscores the high demand for weight loss drugs and supports the argument for continued investor enthusiasm.

Despite the bullish sentiment, uncertainty remains regarding the timing of any potential split. Some analysis suggests that if the stock remains above $1,000 for an extended period, a split could occur in 2026. However, the long-term impact of Foundayo on the company’s growth trajectory is not yet fully established. Additionally, The Motley Fool’s Stock Advisor analyst team did not include Eli Lilly in their current list of 10 best stocks to buy, noting that the company’s strong performance does not automatically guarantee it remains a top pick for all investors.